Ghulam J. Mufti
#126,583
Most Influential Person Now
Ghulam J. Mufti's AcademicInfluence.com Rankings
Ghulam J. Muftiphilosophy Degrees
Philosophy
#5962
World Rank
#8903
Historical Rank
Logic
#3162
World Rank
#4281
Historical Rank
Ghulam J. Muftibiology Degrees
Biology
#8056
World Rank
#11072
Historical Rank
Molecular Biology
#984
World Rank
#1008
Historical Rank
Download Badge
Philosophy Biology
Ghulam J. Mufti's Degrees
- Masters Medicine King's College London
- PhD Molecular Biology King's College London
Why Is Ghulam J. Mufti Influential?
(Suggest an Edit or Addition)Ghulam J. Mufti's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. (2009) (2236)
- Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. (2010) (878)
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. (2013) (535)
- TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. (2011) (442)
- Guidelines for the diagnosis and management of adult aplastic anaemia (2016) (442)
- A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. (2011) (413)
- The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. (2000) (340)
- Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. (2006) (333)
- Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells (2005) (321)
- Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. (1989) (307)
- Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. (2005) (282)
- Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes (2003) (282)
- Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. (2010) (281)
- Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts (2008) (276)
- Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres (2007) (248)
- CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. (2008) (243)
- CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). (2007) (241)
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. (2020) (238)
- TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis (2013) (238)
- Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. (2017) (234)
- Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. (2010) (227)
- Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group (2012) (215)
- Applying synthetic lethality for the selective targeting of cancer. (2014) (206)
- Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. (2014) (205)
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. (2004) (201)
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. (2011) (198)
- Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. (2007) (192)
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (187)
- Immunological abnormalities in myelodysplastic syndromes I. SERUM IMMUNOGLOBULINS AND AUTOANTIBODIES (1986) (185)
- IL‐17‐producing CD4+ T cells, pro‐inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome (2009) (179)
- Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. (2009) (177)
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes (2011) (176)
- BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. (2004) (171)
- Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? (2007) (162)
- Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival (1988) (161)
- Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. (2011) (160)
- CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine (2007) (153)
- Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. (2012) (152)
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. (2016) (151)
- A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. (1996) (146)
- A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia (2003) (145)
- B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease (2012) (144)
- Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin (2007) (143)
- Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia (2014) (142)
- Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways (2001) (140)
- Whole genome scanning as a cytogenetic tool in hematologic malignancies. (2008) (140)
- Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination (2002) (133)
- Functional characterization of CD4+ T cells in aplastic anemia. (2012) (131)
- Role of 4-1BB:4-1BB ligand in cancer immunotherapy (2004) (130)
- Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantati (2006) (129)
- Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. (2002) (127)
- Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. (2002) (126)
- Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. (2014) (124)
- Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine * (2010) (123)
- Increased error-prone non homologous DNA end-joining – a proposed mechanism of chromosomal instability in Bloom's syndrome (2002) (122)
- STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. (2013) (120)
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies (2020) (117)
- Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. (1988) (116)
- Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. (2010) (116)
- p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q) (2014) (116)
- Commitment Point during G0→G1 That Controls Entry into the Cell Cycle (2003) (114)
- Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. (2012) (110)
- Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. (2011) (109)
- Immunological abnormalities in myelodysplastic syndromes II. COEXISTENT LYMPHOID OR PLASMA CELL NEOPLASMS: A REPORT OF 20 CASES UNRELATED TO CHEMOTHERAPY (1986) (109)
- Clinical-cytogenetic correlations in myelodysplasia (preleukemia). (1989) (108)
- Morphological evaluation of monocytes and their precursors (2009) (107)
- Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. (1993) (106)
- Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. (2016) (106)
- A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (2007) (106)
- Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. (2012) (104)
- Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. (1992) (104)
- Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. (2014) (103)
- Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. (2010) (103)
- Pathobiology, classification, and diagnosis of myelodysplastic syndrome. (2004) (101)
- Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. (2007) (100)
- Histone Deacetylase Inhibitors (HDI) Cause DNA Damage in Leukemia Cells: A Mechanism for Leukemia-Specific HDI-Dependent Apoptosis? (2006) (99)
- Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. (2009) (98)
- The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow (2006) (95)
- Autoimmune diseases and myelodysplastic syndromes (2016) (95)
- Bleomycin‐detectable iron in serum from leukaemic patients before and after chemotherapy Therapeutic implications for treatment with oxidant‐generating drugs (1988) (94)
- Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. (1998) (91)
- A Randomized Trial of Hydroxyurea Versus VP 16 in Adult Chronic Myelomonocytic Leukemia (90)
- Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience (2020) (90)
- Chromosomal deletions in the myelodysplastic syndrome. (1992) (90)
- The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome (2013) (88)
- Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced‐intensity conditioning compared with standard preparative regimens (2002) (88)
- Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes (2009) (88)
- Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome (2015) (87)
- Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. (1990) (86)
- An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms (2015) (85)
- Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. (2003) (85)
- Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. (1983) (84)
- Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. (2017) (84)
- Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. (2006) (84)
- SnapShot: Acute myeloid leukemia. (2012) (82)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome (2013) (80)
- Complement abnormalities in acquired lipodystrophy revisited. (2009) (79)
- Spectrum of clinical presentation, treatment and prognosis in a series of eight patients with leukaemia cutis (2006) (78)
- The JAK2 V617F mutation is rare in RARS but common in RARS-T (2006) (78)
- PROSTACYCLIN DEFICIENCY IN THROMBOTIC THROMBOCYTOPENIC PURPURA (1979) (76)
- Guidelines for the diagnosis and management of adult myelodysplastic syndromes (2014) (76)
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes (2008) (76)
- Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (2015) (75)
- Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. (2005) (74)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Emberger syndrome—Primary lymphedema with myelodysplasia: Report of seven new cases (2010) (74)
- SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment (2015) (73)
- Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? (2009) (72)
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells (2015) (72)
- Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. (2010) (72)
- Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. (2013) (71)
- Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C (2010) (70)
- Versatile humanized niche model enables study of normal and malignant human hematopoiesis (2017) (68)
- Methylation inhibitor therapy in the treatment of myelodysplastic syndrome (2005) (68)
- BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. (2007) (67)
- Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
- Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes (2006) (67)
- Myelodysplastic syndromes: natural history and features of prognostic importance. (1986) (62)
- Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation (2017) (59)
- Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies (2013) (58)
- In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis--possible evidence of an occult myeloproliferative state. (1990) (58)
- Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. (1989) (56)
- Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. (2007) (56)
- Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). (1996) (55)
- Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. (1983) (53)
- Targeted therapies in myeloid leukemia. (2004) (53)
- The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions (2018) (53)
- Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. (1993) (52)
- Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King's College Hospital. (2015) (52)
- Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission (2008) (51)
- MANAGEMENT OF ADULT T‐CELL LEUKAEMIA/LYMPHOMA (1998) (50)
- Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival (2009) (50)
- Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. (1999) (50)
- Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes (2006) (50)
- Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience (2010) (49)
- Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML (2010) (49)
- Outcome of BEAM‐autologous and BEAM‐alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma (2008) (49)
- IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. (2005) (48)
- Phenotypic and functional characteristics of monocyte‐derived dendritic cells from patients with myelodysplastic syndromes (1999) (47)
- The Role of Apoptosis in the Pathogenesis of the Myelodysplastic Syndromes (2001) (46)
- Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy (2007) (46)
- A comprehensive diagnostic approach using galactomannan, targeted β‐d‐glucan, baseline computerized tomography and biopsy yields a significant burden of invasive fungal disease in at risk haematology patients (2015) (46)
- Apoptosis and its significance in MDS: controversies revisited. (1999) (45)
- Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes (2013) (45)
- Valuation of transfusion-free living in MDS: results of health utility interviews with patients (2009) (45)
- Excessive Apoptosis in Low Risk Myelodysplastic Syndromes (MDS) (2000) (45)
- The cytokine receptor superfamily. (1991) (44)
- Rituximab therapy for the type B syndrome of severe insulin resistance. (2004) (44)
- Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome (2019) (44)
- Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. (2022) (44)
- Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells (2005) (44)
- Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes (2013) (43)
- The Myelodysplastic Syndromes: A Matter of Life or Death (2003) (42)
- Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells (2003) (42)
- Reducing MCM levels in human primary T cells during the G0→G1 transition causes genomic instability during the first cell cycle (2010) (42)
- Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. (2018) (42)
- The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. (1997) (42)
- A guide to risk assessment in the primary myelodysplastic syndrome. (1992) (41)
- Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (2009) (41)
- Ras and myelodysplasia: lessons from the last decade. (1996) (41)
- Tumor-derived IL-6 may contribute to the immunological defect in CLL (2008) (40)
- Imbalance of effector and regulatory CD4 T cells is associated with graft-versus-host disease after hematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab (2009) (40)
- Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant R (2016) (40)
- Human Erythroid Progenitors Are Directly Infected by SARS-CoV-2: Implications for Emerging Erythropoiesis in Severe COVID-19 Patients (2021) (39)
- Granulocyte colony‐stimulating factor improves function of neutrophils from patients with acute liver failure (2000) (38)
- Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. (1997) (38)
- Delayed attainment of full donor chimaerism following alemtuzumab‐based reduced‐intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes (2007) (38)
- Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. (2005) (37)
- TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKAEMIA WITH LOW DOSE ETOPOSIDE (1989) (37)
- Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions (2013) (37)
- Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy. (1988) (36)
- Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. (2011) (36)
- Possible co-existence of RAS activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. (1995) (36)
- Crucial roles for protein kinase C isoforms in tumor-specific killing by apoptin. (2010) (35)
- Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. (2019) (35)
- Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease (2008) (35)
- High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS) (2015) (34)
- Chronic relapsing remitting Sweet syndrome – a harbinger of myelodysplastic syndrome (2015) (34)
- Abnormal localization of immature precursors (ALIP) in the bone marrow of myelodysplastic syndromes: current state of knowledge and future directions. (1991) (34)
- Multicentric reticulohistiocytosis. Detailed immunophenotyping confirms macrophage origin. (1990) (34)
- The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) (2008) (34)
- Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2012) (34)
- Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. (2017) (34)
- Reactivation of hepatitis B virus infection in patients with hematologic disorders (2019) (34)
- Mutations in histone modulators are associated with prolonged survival during azacitidine therapy (2015) (33)
- Cyclin D2 controls B cell progenitor numbers (2003) (33)
- An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia (2006) (32)
- Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide (2012) (32)
- Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission (2017) (32)
- A functional assay for microRNA target identification and validation (2010) (32)
- Severe deafness in systemic lupus erythematosus: its immediate relief by plasma exchange. (1982) (32)
- Hyperinfection with strongyloides after treatment for adult T cell leukaemia-lymphoma in an African immigrant. (1988) (32)
- Immunobiology (2020) (32)
- Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome. (2012) (31)
- Apoptosis in the myelodysplastic syndromes. (2003) (31)
- Effi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised , open-label , phase III study (2012) (31)
- Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. (2013) (31)
- Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. (2018) (30)
- Monocytic skin infiltration in chronic myelomonocytic leukaemia. (1986) (30)
- Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study (2014) (29)
- Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation (2018) (29)
- Myelodysplastic syndromes: from morphology to molecular biology. Part II. The molecular genetics of myelodysplasia. (1993) (29)
- Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) (2006) (29)
- Hydroxyurea treatment of meningiomas: a pilot study. (2006) (29)
- RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004). (2009) (29)
- Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukaemia. (1985) (29)
- Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data (2007) (29)
- Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten‐eleven translocation 2 mutations in budd‐chiari syndrome and their impact on thrombotic complications post Liver Transplantation (2012) (28)
- Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. (2001) (28)
- Differentially expressed genes in adult familial myelodysplastic syndromes (2004) (28)
- Acquired sideroblastic anaemia induced by a copper-chelating agent. (1996) (28)
- Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis (2018) (28)
- Bilateral adrenal lymphoma presenting as Addison's disease. (1989) (27)
- Successful Treatment of Post‐Transfusion Purpura with High Dose Immunoglobulins after Lack of Response to Plasma Exchange (1985) (27)
- Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases. (1996) (27)
- Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. (2011) (27)
- Life-threatening motor neurotoxicity in association with bortezomib. (2006) (26)
- NON-INVASIVE ISOLATION OF CONSTITUTIONAL DNA FOR GENETIC ANALYSIS (1989) (26)
- Epigenetics of human T cells during the G0-->G1 transition. (2009) (26)
- Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura. (2006) (26)
- Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. (2006) (26)
- Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (2017) (26)
- Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study (2011) (25)
- The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT (2013) (25)
- Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. (2006) (25)
- Human CD80/IL2 lentivirus‐transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a phase I clinical study (2009) (25)
- Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions (2003) (25)
- Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data (2013) (25)
- Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia (2021) (24)
- Precipitation of porphyria cutanea tarda by imatinib mesylate? (2003) (24)
- Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells (2017) (24)
- Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry (2012) (24)
- FLT3 and JAK2 Mutations in Acute Myeloid Leukemia Promote Interchromosomal Homologous Recombination and the Potential for Copy Neutral Loss of Heterozygosity. (2017) (24)
- Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. (2014) (24)
- Antiapoptotic Microenvironment of Acute Myeloid Leukemia (2004) (23)
- High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRATM). (2004) (23)
- Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia. (1993) (23)
- Myelodysplastic syndromes: who and when in the course of disease to transplant. (2012) (23)
- Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT (2017) (23)
- The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. (2005) (22)
- Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. (2007) (22)
- Differentiation induction in myelodysplasia and acute myeloid leukaemia: use of synergistic drug combinations. (1987) (22)
- PNP with Waldenström's macroglobulinaemia (2005) (22)
- VERY-LOW-DOSE CYTARABINE FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA IN THE ELDERLY (1986) (22)
- The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma. (1996) (21)
- An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. (2013) (21)
- Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). (2012) (21)
- Mobilized peripheral blood stem cells compared with bone marrow from HLA‐identical siblings for reduced‐intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT (2012) (21)
- Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities (2015) (21)
- CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis. (2015) (20)
- CD4+ lymphocytopenia due to common variable immunodeficiency mimicking AIDS. (1994) (20)
- Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms. (2018) (20)
- Development of a whole cell vaccine for acute myeloid leukaemia (2005) (20)
- Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes. (2005) (20)
- Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative (2008) (20)
- Eltrombopag: a stem cell cookie? (2014) (20)
- Changing the treatment paradigm in myelodysplastic syndromes. (2008) (19)
- Allogeneic transplantation for myelodysplastic syndrome (MDS). (2007) (19)
- Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients (2010) (19)
- Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. (2012) (19)
- AKT1 (E17K) Mutation in Pancreatic Cancer (2008) (19)
- Randomized multicentre study of ciprofloxacin and azlocillin versus gentamicin and azlocillin in the treatment of febrile neutropenic patients. (1990) (19)
- Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature (2007) (19)
- Heterozygous RTEL1 variants in bone marrow failure and myeloid neoplasms. (2018) (18)
- Cardiac presentation of ALK positive anaplastic large cell lymphoma (2005) (18)
- Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes (2014) (18)
- Analysis of CHK2 in patients with myelodysplastic syndromes. (2002) (18)
- Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation (2019) (18)
- Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party (2017) (17)
- The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes (2015) (17)
- Bilateral Retinal Vasculopathy Associated with Autosomal Dominant Dyskeratosis Congenita (2013) (17)
- Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors (2008) (16)
- Detection and Clinical Significance of Bone Marrow Micrometastases in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma (2005) (16)
- High incidence of therapy‐related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders (2006) (16)
- Sarcoidosis and haematological malignancies: is there an association? (2008) (16)
- Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK (2012) (16)
- Fluorescence‐based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells (2012) (16)
- Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag (2019) (16)
- Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation (2018) (16)
- Haematopoietic stem cell transplantation for acquired aplastic anaemia (2013) (16)
- Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab (2010) (16)
- Pyogenic abscesses in the myelodysplastic syndrome. (1989) (16)
- Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes (2017) (16)
- Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. (2019) (16)
- RPL27A is a target of miR-595 and may contribute to the myelodysplastic phenotype through ribosomal dysgenesis (2016) (16)
- Recurrent Novel Regions of Uniparental Disomy and Homozygous Deletions in Mycosis Fungoides Identified Using High Resolution Single Nucleotide Polymorphism Analysis. (2009) (16)
- Erythema following imatinib mesylate (2003) (16)
- Erythropoietic uroporphyria associated with myeloid malignancy is likely distinct from autosomal recessive congenital erythropoietic porphyria. (2011) (15)
- Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis (2015) (15)
- Quantification of HIV by PCR in monocytes and lymphocytes in patients receiving antiviral treatment and low dose recombinant human granulocyte macrophage colony stimulating factor. (1994) (15)
- Consistent interstitial chromosomal deletions in myeloid malignancies and their correlation with fragile sites. (1993) (15)
- Familial MDS with 5q — abnormality (1993) (15)
- Somatic Mutations in Aplastic Anemia. (2018) (15)
- Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80 (2010) (14)
- Early and Sustained Response to Azacytidine in High-Risk MDS Patients with Monosomy 7 Correlates with Increased Apoptosis and Not CDKN2B Demethylation. (2005) (14)
- Plasmapheresis and a placebo procedure in autoerythrocyte sensitisation. (1981) (14)
- In vitro immune modulation by antibodies coupled to tumour cells (1997) (14)
- Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391-5396. (2013) (14)
- Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia (2013) (14)
- Application of the international scoring system for myelodysplasia to M.D. Anderson patients [3] (multiple letters) (1997) (14)
- Myelodysplastic syndromes: Their history, evolution and relation to acute myeloid leukaemia (1986) (14)
- Thalidomide therapy for low-risk Myelodysplasia. (2005) (14)
- Basic isoferritin and hypercalcaemia in renal cell carcinoma (1982) (13)
- Allogeneic stem cell transplantation in MDS: how? When? (2013) (13)
- Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (2019) (13)
- Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomize (2014) (13)
- Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation (2007) (13)
- Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome (2006) (13)
- Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. (2009) (13)
- Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT (2017) (13)
- Low-dose filgrastim therapy for chronic neutropenia. (1993) (13)
- Myelodysplastic syndrome can propagate from the multipotent progenitor compartment (2017) (13)
- MANAGEMENT OF MYELODYSPLASTIC SYNDROMES (1993) (12)
- Myelodysplasia syndromes during pregnancy (1991) (12)
- Impact of T‐cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party (2018) (12)
- Novel ADA2 mutation presenting with neutropenia, lymphopenia and bone marrow failure in patients with deficiency in adenosine deaminase 2 (DADA2) (2019) (12)
- Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. (2015) (12)
- Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. (2018) (12)
- Co-infection with HTLV-I/II and HIV-1 (1990) (12)
- Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men (2017) (12)
- Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen. (2009) (12)
- JAK V617F missense mutation is absent in pancreatic cancer (2007) (12)
- Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party (2014) (12)
- Clinical significance of acquired somatic mutations in aplastic anaemia (2016) (11)
- Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia (2003) (11)
- Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial (2014) (11)
- Mixed donor chimaerism in recipient fingernails following reduced-intensity conditioning haematopoietic SCT (2008) (11)
- Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation. (2016) (11)
- JAK Inhibition Reduces CD25 high CD27+ FOXp3+ T Regulatory Cells and Causes a Silencing Of T Effector Cells In Patients With Myeloproliferative Neoplasms Whilst Promoting a TH17 Phenotype (2013) (11)
- Optimised SEREX technique for the identification of leukaemia-associated antigens. (2002) (11)
- Liver transplantation for HCV‐related cirrhosis in a patient with gastric mucosa‐associated lymphoma (MALToma) pretreated with rituximab (2005) (11)
- British Society for Haematology guidelines for the management of adult myelodysplastic syndromes (2021) (11)
- Hypoalbuminaemia after prolonged treatment with recombinant granulocyte macrophage colony stimulating factor. (1990) (10)
- Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial (2008) (10)
- GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways (2016) (10)
- Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients. (2020) (10)
- Prodromal cutaneous lesions in adult T-cell leukaemia/lymphoma (1990) (10)
- Treg sensitivity to FasL and relative IL-2 deprivation drive Idiopathic Aplastic Anemia immune dysfunction. (2020) (10)
- Effects on erythropoiesis of alemtuzumab‐containing reduced intensity and standard conditioning regimens (2008) (10)
- Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. (2003) (10)
- High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells. (2003) (9)
- Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H. (2001) (9)
- Primary myelodysplastic syndrome with complex chromosomal rearrangements in a patient with Klinefelter's syndrome. (1986) (9)
- The Aplasia-Leukaemia Syndrome (1983) (9)
- Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis. (2019) (9)
- A review of 100 consecutive cases of myelodysplastic syndrome with skin disorders (2008) (9)
- The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes. (1994) (9)
- Epstein-Barr virus-related post-transplant lymphoproliferative disorder with t(9;14)(p11-12;q32). (2003) (9)
- COEXISTENT LYMPHOID OR PLASMA CELL NEOPLASMS (1987) (9)
- Ectopic humanized mesenchymal niche in mice enables robust engraftment of myelodysplastic stem cells. (2020) (9)
- Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma. (1983) (9)
- Modification of standard proteinase K/phenol method for extraction of DNA from small tumour biopsies. (1993) (9)
- Extending the role of allogeneic stem-cell transplantion (2001) (9)
- Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability. (2015) (9)
- Acute transformation of a myeloproliferative state in sideroblastic anaemia with abnormal karyotype. (1982) (9)
- RESULTS OF A PHASE 1 STUDY OF BMN 673, A POTENT AND SPECIFIC PARP-1/2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES (2014) (9)
- Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party (2015) (9)
- Functional reconstruction of human AML reveals stem cell origin and vulnerability of treatment-resistant MLL-rearranged leukemia (2021) (8)
- Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR) (2008) (8)
- Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature. (2021) (8)
- miR‐181c‐BRK1 axis plays a key role in actin cytoskeleton‐dependent T cell function (2018) (8)
- Nonhomologous End-Joining Proteins Is Associated with DNA Damage at Sites that Recruit Key Increased Error-prone NHEJ Activity in Myeloid Leukemias (2003) (8)
- The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (2018) (8)
- An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial. (2021) (8)
- The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia. (2019) (8)
- False positive results of galactomannan ELISA assay in haemato-oncology patients: a single centre experience. (2007) (8)
- Hemophagocytosis: a potential complication in small bowel transplantation. (1998) (8)
- Allogeneic stem cell transplantation (SCT) in MDS: Interim results of outcome following non-myeloablative conditioning compared to standard preparative regimens. (2000) (8)
- Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): Effects on overall survival (OS) (2008) (8)
- Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes (2014) (8)
- Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. (2017) (8)
- Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7 (2020) (8)
- Exercise-induced urticaria and angio-oedema with relief from cromoglycate insufflation. (1983) (7)
- T‐cell lymphoblastic lymphoma presenting as an intra‐muscular mass (2006) (7)
- Diagnostic algorithm for lower-risk myelodysplastic syndromes (2018) (7)
- Imatinib mesylate in myelofibrosis: Preliminary results show early sustained improvements in platelet counts and splenomegaly. (2002) (7)
- Primary effusion lymphoma in an HIV‐negative man (2011) (7)
- Transplant‐acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies (2014) (7)
- Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells (2018) (7)
- Correction: B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease (2012) (7)
- The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients. (2017) (7)
- British Society for Haematology guidelines for the diagnosis and evaluation of prognosis of Adult Myelodysplastic Syndromes (2021) (7)
- Human CD80/IL2 lentivirus transduced acute myeloid leukaemia cells enhance cytolytic activity in vitro in spite of an increase in regulatory CD4+ T cells in a subset of cultures (2009) (7)
- BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma (1992) (7)
- Hypoplastic MDS Is a Distinct Clinico-Pathological Entity with Somatic Mutations Frequent in Patients with Prior Aplastic Anaemia with Favorable Clinical Outcome (2014) (7)
- Acquired factor V inhibitor after haematopoietic stem cell transplantation (2007) (7)
- Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML (2015) (7)
- Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. (2014) (6)
- Functional Characterization of CD4(+) T-Cells in Aplastic Anemia (AA) (2011) (6)
- Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study (2020) (6)
- Hairy cell leukaemia and Legionnaires' disease. (1985) (6)
- The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients. (2011) (6)
- The aplasia-leukaemia syndrome. Aplastic anaemia followed by dyserythropoiesis, myeloproliferative syndrome and acute myeloid leukaemia. (1983) (6)
- Romiplostim in Thrombocytopenic Patients (Pts) with Low-Risk or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) Results in Reduced Bleeding without Impacting Leukemic Progression: Updated Follow-up Results from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study (2015) (6)
- Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study (2020) (6)
- Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine. (2007) (6)
- Mass Cytometry Reveals PD1 Upregulation Is an Early Step in MDS Disease Progression (2016) (6)
- Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI) (2019) (6)
- The myelodysplastic syndromes. (1987) (6)
- The role of a critical care outreach service in the management of patients with haematological malignancy (2019) (5)
- Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia (2016) (5)
- Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? (2014) (5)
- Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial (2021) (5)
- Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. (2019) (5)
- Early and late‐onset veno‐occlusive disease/sinusoidal syndrome post allogeneic stem cell transplantation – a real‐world UK experience (2020) (5)
- Neoantigens in MDS Are Associated with Two Novel CD4+ T Cell Subsets and Improved Overall Survival (2017) (5)
- Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML. (2006) (5)
- Alemtuzumab-based reduced-intensity conditioning allogeneic transplantation for myeloma and plasma cell leukemia - a single-institution experience. (2011) (5)
- Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. (2014) (5)
- Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT (2021) (5)
- National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03) (2011) (5)
- Successful treatment of aplastic anaemia associated with HIV infection with eltrombopag: implications for a possible immunomodulatory role (2014) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP). (2008) (5)
- European Multi-Centre Study on the Use of Anti-Thymocyte Globulin in the Treatment of Myelodysplastic Syndromes. (2005) (5)
- Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy—Is it prognostic?—a single-center retrospective study (2021) (5)
- Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. (2019) (5)
- Drug rash with eosinophilia and systemic symptoms and graft‐versus‐host disease developing sequentially in a patient (2009) (5)
- Alemtuzumab vs anti‐thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning (2018) (5)
- Somatic Mutations Implicated In Myeloid Malignancies Are Frequent In Idiopathic Aplastic Anaemia and Its Relevance To Disease Classification and Treatment- a Comprehensive Analysis Of 150 Patients (2013) (4)
- Impact of Human Leucocyte Antigen epitope matched platelet transfusions in alloimmunised aplastic anaemia patients (2020) (4)
- AML-derived immunomodulatory factor(s) inhibit T cell cytokine secretion and proliferation via inhibition of NF-ATc activation and failure to upregulate C-MYC. (1999) (4)
- Treatment With Romiplostim, a Thrombopoietin-Receptor Agonist, In Thrombocytopenic Patients With Low Or Intermediate-1 Risk Myelodysplastic Syndrome: Updated Follow-Up Results For Acute Myeloid Leukemia and Survival From a Randomized, Double-Blind, Placebo-Controlled Study (2013) (4)
- Therapy of myelodysplastic syndromes: advances and perspectives. Innsbruck, Austria, October 7-10, 1990. (1991) (4)
- 5-Azacytidine Specifically Depletes Regulatory T Cells (Tregs) in Myelodysplastic Syndrome (MDS) Patients (2011) (4)
- Evolution of a terminal deoxynucleotidyl transferase-positive lymphoma from a chronic T cell lymphocytosis. (2009) (4)
- Pre‐symptomatic (Baseline) computed tomography predicts invasive pulmonary aspergillosis in high‐risk adult haemato‐oncology patients (2018) (4)
- Myelodysplastic relapse of de-novo AML: a heterogeneous entity? (1987) (4)
- PROLONGED SURVIVAL IN HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS (PTS) WITH-7/DEL(7Q) TREATED WITH AZACITIDINE (AZA) (2008) (4)
- Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs) (2015) (4)
- Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes (2014) (4)
- Clinical efficacy of rituximab in the treatment of pemphigus vulgaris: a 10-year follow-up. (2019) (4)
- recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in adults (2013) (4)
- Prognostic and Predictive Impact of Small PNH Clones in a Large Cohort of Patients with Myelodysplastic Syndromes and Aplastic Anemia: A Single-Center Experience (2018) (4)
- Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction. (2005) (4)
- Cutaneous Presentation of Fusarium Solani Infection in a Bone Marrow Transplant Recipient (1996) (4)
- Reduced-intensity allogeneic haematopoietic stem cell transplantation(HSCT) in 75 patients with myelodysplastic syndromes following conditioning with fludarabine, busulphan and alemtuzumab. (2003) (4)
- NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders (2015) (4)
- The Kingscord model: a public cord blood collection service (2009) (4)
- 22 Familial myelodysplastic syndromes: A key to understanding leukaemogenesis? (1997) (4)
- Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases (2013) (4)
- MicroRNA Expression Profiling of High and Low Risk MDS (2008) (3)
- Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes (2011) (3)
- Anti-tumor immunity in a model of acute myeloid leukemia (2009) (3)
- Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience (2019) (3)
- C005 New definitions for blast cells in AML and MDS with validation by virtual microscopy (2007) (3)
- Sweet's syndrome and myelodysplasia (2004) (3)
- Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS) (2005) (3)
- High Resolution Mass Cytometry (CyTOF) in Aplastic Anaemia (AA) Can Identify an Aberrant Treg Subset with Pro-Inflammatory Properties, Predicting Poor Response to Immunosuppressive Therapy (2014) (3)
- Reduced intensity conditioned allografts for chronic myeloid leukaemia: A study from the chronic leukaemia working party of the EBMT. (2002) (3)
- CD38 expression in B-CLL is dynamic and changes due to contact with activating stimuli found within the leukaemic microenvironment (2006) (3)
- TREATMENT FOR MYELODYSPLASTIC SYNDROMES (1987) (3)
- Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI. (2005) (3)
- Predicting Thrombotic Complications after Liver Transplantation in Patients with Budd Chiari Syndrome (2010) (3)
- Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients (2018) (3)
- Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (2022) (3)
- Challenges in Liver Transplantation for Common Variable Immunodeficiency-related Liver Disease a Case Series and Systematic Review (2021) (3)
- Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy (2006) (3)
- Impact of the intensity of conditioning regimen in 144 patients with follicular lymphoma (FL) receiving a matched unrelated donor stem cell transplant (MUD-SCT): An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (LWP-EBMT) (2008) (3)
- Ectopic Humanized Mesenchymal Niche in Mice Enables Robust Engraftment of Myelodysplastic Stem Cells. (2021) (3)
- Characterization of an AML-derived immunomodulatory factor(s) that inhibit T cell activation and the signal transduction pathways involved. (2000) (3)
- Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004) (2010) (3)
- An epitope-based approach to use of HLA matched platelets for transfusion: a noninferiority, cross-over, randomised trial. (2020) (3)
- UK Estimates of Burden of Disease Associated with Management of Intermediate-2 or High-Risk Myelodysplastic Syndromes (2011) (3)
- Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT (2016) (3)
- Angio-immunoblastic lymphadenopathy with hypogammaglobulinaemia complicated by miliary tuberculosis. (1985) (3)
- Treatment of pemphigus vulgaris with rituximab (2009) (3)
- Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial (2019) (3)
- Kings Health Partners 17 Gene Amplicon Panel for Next Generation Sequencing One Stop Mutational Assessment In Myeloid Malignancies (2011) (3)
- Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA) (2008) (3)
- Non-Caseating Granulomata Associated with Hypocellular Myelodysplastic Syndrome (2000) (3)
- CLORETAZINE™ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS). (2005) (3)
- The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes (2015) (3)
- Outcome of Second Allogeneic Transplants Using Reduced Intensity Conditioning Following Relapse after an Initial Allogeneic Transplant. (2006) (3)
- Contrasting Roles of Th1 and Th17 Cells in Aplastic Anaemia (AA) and Myelodysplastic Syndrome (MDS). (2009) (3)
- IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes. (2006) (2)
- AN EVALUATION OF THE ASSOCIATION OF CDKN2B (P15) DNA METHYLATION WITH RESPONSE AND SURVIVAL IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) TREATED IN THE AZA-001 TRIAL (2010) (2)
- Real-Time Detection of PML-RARA and RARA-PML Fusion Transcripts in High Risk Acute Promyelocytic Leukemia (APL) Treated with Arsenic Trioxide (ATO): Implications for Realization of Pre-Emptive Therapy for Molecular Relapse. (2006) (2)
- Telomere Length In MDS Patients Bone Marrow Is Highly Correlated with Complex Cytogenetics, IPSS Risk Groups and Transfusion Dependency, (2011) (2)
- Opiates for sickle-cell crisis? (multiple letters) [8] (1998) (2)
- Mutations in Cohesin Complex As Potential Targets for Therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome (2015) (2)
- Analysis of BEAM (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) versus high dose Melphalan (HDM) with autologous rescue in multiple myeloma(MM) (2004) (2)
- Hypoplastic Myelodysplastic Syndrome: Clinical, Histopathological and Molecular Characterization (2017) (2)
- Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes. (1999) (2)
- Polycythemia rubra vera and Hairy Cell Leukaemia / Reply (1985) (2)
- Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations (2017) (2)
- Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2008) (2)
- A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT). (2017) (2)
- Pre-Emptive Donor Lymphocyte Infusion Corrects Deficiencies in the T-Cell Repertoire after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte-Depletion for Acute Myeloid Leukaemia and Myelodysplastic Syndromes (2016) (2)
- Mucous membrane pemphigoid following reduced intensity conditioning allogeneic haematopoietic SCT for biphenotypic leukaemia (2010) (2)
- Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy (2013) (2)
- Anti‐type M phospholipase A2 receptor antibody‐positive membranous nephropathy as a part of multi‐system autoimmune syndrome post‐allogeneic stem cell transplantation (2018) (2)
- Genotype study of non-Hodgkin's lymphoma. (1995) (2)
- MYELOID NEOPLASIA STAT 3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients (2013) (2)
- Use of the galactomannan ELISA in the detection of invasive aspergillosis: a retrospective review and potential pitfalls in application (2004) (2)
- The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS) (2015) (2)
- Relapse of lymphoma in the heart after a 10-year remission. (1984) (2)
- EFFECT OF AZACITIDINE (AZA) vs LOW-DOSE ARA-C (LDAC) ON OVERALL SURVIVAL (OS), HEMATOLOGIC RESPONSE, TRANSFUSION INDEPENDENCE, AND SAFETY IN PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) (2008) (2)
- Single and Dual Targeting Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia (2020) (2)
- DO CD34+ CELL COUNTS PREDICT HAEMOPOIETIC RECOVERY AFTER AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION (ABSCT)? (1995) (2)
- Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate. (2004) (2)
- Porphyria in association with myelodysplastic syndrome (2005) (2)
- Investigation of the Impact of Myelodysplasia (MDS) From the Patients' Perspective (2011) (2)
- The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes (2015) (2)
- Syndromes International Scoring System for Evaluating Prognosis in Myelodysplastic (2010) (2)
- King’s College Hospital FCC Conditioning for Severe Aplastic Anemia Induces Tolerance with Mixed T-Cell Chimerism and Extremely Low Incidence of Gvhd (2014) (2)
- Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R (2014) (2)
- PTU-070 Liver failure in association with hepatic amyloidosis and the role of liver transplantation: the King's College Hospital Experience (2010) (2)
- Myelodysplasia (MDS) patients' Experiences with Blood Transfusions (2011) (2)
- Microsatellite Instability (MSI) In High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Cells Promotes Frameshift Mutations In DNA Repair Genes Indications for PARP Inhibitor Therapy (2010) (2)
- 5-Azacytidine in the Treatment of High Risk Myelodysplastic Syndromes: Clinical Response Can Occur without Demethylation of the CDKN2B , CDKN1A or TP73 Gene Promoters. (2004) (2)
- Advances in malignant hematology (2013) (2)
- Comparison of Peripheral Blood and Bone Marrow Molecular Profiling in Primary Myelodysplastic Syndromes (MDS) (2014) (2)
- P122 Value of transfusion-free living in myelodysplastic syndromes (MDS): results of health utility interviews with patients (2007) (2)
- Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis. (2011) (2)
- Reduced intensity conditioned volunteer unrelated donor transplants using alemtuzumab are safe and effective in older patients with myelodysplastic syndromes (2005) (2)
- Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort (2019) (2)
- Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study (2013) (2)
- Results of an international phase 2study of the oral farnesyl transferase inhibitor (FTI) tipifarnib (ZARNESTRA®) in patients with high-risk myelodysplastic syndrome (MDS) (2005) (2)
- IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML (2004) (2)
- Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series (2019) (2)
- Polycythemia rubra vera and hairy cell leukemia. (1985) (2)
- OP26 Predicting thrombotic complications after liver transplantation in patients with Budd Chiari syndrome (2010) (2)
- ABT 737 BCL-2 INHIBITOR TARGETS LEUKEMIC STEM CELLS IN MOUSE MODELS OF MYELOID (PRE)LEUKAEMIA (2009) (2)
- MOBILISATION FAILURE IS PREDICTIVE OF POOR OVERALL SURVIVAL AFTER AUTOLOGOUS TRANSPLANTATION (2008) (2)
- Development and Validation of a Model to Predict Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). (2012) (2)
- Comparative analysis of melphalan versus busulphan T‐cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia (2019) (2)
- Diagnosis and Prognosis: Molecular (2018) (2)
- Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status (2008) (2)
- Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome. (2006) (2)
- Reduced-intensity rituximab-BEAM-CAMPATH allogeneic transplantation for indolent non-Hodgkin's lymphoma. (2001) (1)
- Identification of a novel cancer-testis antigen as a target for the immunotherapy of acute myeloid leukaemia (AML) (2009) (1)
- Poly ADP Ribose Polymerase (PARP) Inhibitors Induce Apoptosis Alone or Synergistically with Histone Deacetylase Inhibitors in Primary Acute Myeloid Leukemic Patient Cells (2008) (1)
- Sweet's syndrome associated with myeloid malignancies and administration of granulocyte colony-stimulating factor (2005) (1)
- tipifarnib in intermediate- to high-risk myelodysplastic syndrome A multicenter phase 2 study of the farnesyltransferase inhibitor (2012) (1)
- Haemophagocytic lymphohistiocytosis (HLH) following orthotopic liver transplantation: a single centre report of 37 cases (2006) (1)
- miR-181c modulates T cell function by regulating the expression of BRK1 (2016) (1)
- Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation — 5 Years Single Centre Experience (2017) (1)
- CD25high Foxp3 regulatory T cells in myelodysplastic syndrome (MDS) (2007) (1)
- P128 Transfusion independence (TI) in patients with myelodysplastic syndromes (MDS) treated with azacitidine (AZA) (2009) (1)
- Inhibition of Poly ADP Ribose Polymerase (PARP) Activity Exerts Cytotoxic Effects on Chromosomal Instability Syndrome and Leukaemic Cell Lines: Potential for Anti-Leukaemia Therapy. (2006) (1)
- Gene expression using adenoviral vectors in primary acute myeloid leukaemia cells. (1999) (1)
- Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease. (2007) (1)
- David Galton, myelodysplasia and little me! (2007) (1)
- Simultaneous bilateral pleomorphic adenomas of the parotid glands with unilateral tyrosine rich crystalloids (1)
- Advances in Malignant Hematology: Saba/Advances in Malignant Hematology (2011) (1)
- Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib (2010) (1)
- Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINE™ (VNP40101M). (2005) (1)
- Alemtuzumab containing reduced intensity conditioning regimen is safe and effective in myelofibrosis. (2003) (1)
- CAMPATH-1H reduces the risk of graft versus host disease following allogeneic hematopoietic stem cell transplantation and minimally myelosuppressive conditioning treatment with low dose total body irradiation and Cyclosporine/Mycophenotate Mofetil immunosuppression. (2001) (1)
- p 53 protein expression independently predicts outcome in patients with lowerrisk lowerrisk lowerrisk myelodysplastic syndromes with del ( 5 q ) (1)
- Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML (2011) (1)
- Emerging therapeutic and supportive care approaches for the myelodisplastic syndromes. (2004) (1)
- A novel zinc finger gene, ZNF465, is inappropriately expressed in acute myeloid leukaemia cells (2015) (1)
- MDS-171: Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (1)
- A Comprehensive Diagnostic Approach Improves the Diagnostic Accuracy of Invasive Fungal Disease (IFD) in Adult Haemato-Oncology Patients Undergoing HSCT or High Dose Chemotherapy- Results of the King's Prospective Aspergillosis Study (NCT00816088) (2011) (1)
- Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. (2004) (1)
- Whole Exome Sequencing Reveals Acquired SF3B1 Mutations Defining Patients with Acquired Idiopathic Sideroblastic Anaemia (2011) (1)
- Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML). (2005) (1)
- Failure to mobilise is not a poor prognostic factor in myeloma (2007) (1)
- Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study (2012) (1)
- Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy (2014) (1)
- The use of rituximab as a single therapy for the treatment of severe recalcitrant pemphigus (2008) (1)
- Allogeneic stem cell transplantation with matched related and unrelated donors for patients with refractory anemia: T-cell depletion and reduced intensity regimens are associated with increased relapse risk (2003) (1)
- SNP-Array Based Karyotyping Complements Routine Cytogenetics in Diagnosis and Risk Stratification Schemes of MDS (2008) (1)
- A randomized, open-label, phase II study of CC-486 (oral azacitidine), alone or in combination with durvalumab (MEDI4736), in patients (pts) with myelodysplastic syndromes (MDS) unresponsive to prior parenteral azacitidine or decitabine. (2016) (1)
- B446 NK Cell—Mediated Immunologic Responses Against Myeloma by B7-1(CD80)/IL-2 Immune Gene Therapy (2009) (1)
- Genetic instability as an area of potential therapeutic intervention (2007) (1)
- Myeloid Leukemia? Repair: A Model for Genomic Instability with Progression in Reactive Oxygen Species, DNA Damage, and Error-Prone (2007) (1)
- 221 Occurrence of trisomy 8 (+8) in patients with Low- or Int-1-risk MDS with deletion 5q [del(5q)] treated with lenalidomide (2011) (1)
- Internal Tandem Duplication Mutation Of FLT3 (FLT3/ITD) Induces Increased Homologous Recombination DNA Repair Activity, Drug Resistance and Sister Chromatid Exchanges In Acute Myeloid Leukaemia (AML) (2013) (1)
- Effect of leukemia cell microenvironment on the differentiation of dendritic cells from normal monocytes: A phenotypic and functional analysis. (1999) (1)
- HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS (2012) (1)
- Array-Based Karyotyping and Genotyping Demonstrates a Non Random Selection of Allelic Variants of Genes in Clones with 5q31 Deletion Mutants (2008) (1)
- The non-transplant treatment of myelodysplastic syndromes-what's on the horizon? (2012) (1)
- Suppression of T cell proliferation by AML cells is an early event in G0 to G1 transition involving inhibition of pRB phosphorylation by cyclin D-cdk6/4. (2000) (1)
- Pathology of bone marrow failure syndromes (2015) (1)
- Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities (2013) (1)
- TP53 Mutations Are Restricted Predominantly to 5q- Syndrome and Myelodysplastic Syndrome Patients with Complex Cytogenetics, and Correlate with Adverse Prognosis (2011) (1)
- Immunosuppressive Therapy for Aplastic Anemia (2017) (1)
- Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently (2005) (1)
- Alemtuzumab Used with Fludarabine and Cyclophosphamide (FCC) for Stem Cell Transplantation in Acquired Aplastic Anemia Is Associated with a Low Risk of Graft Versus Host Disease and Viral Infections and with Sustained Engraftment. (2009) (1)
- STAT3-Mutations Indicate the Presence of Subclinical Self-Reactive Cytotoxic T Cell Clones in Aplastic Anemia and Myelodysplastic Syndromes (2012) (1)
- Monocistronic high titre vectors for targeted expression of multiple therapeutic genes (2004) (1)
- The Myelodysplastic Syndromes (MDS) Foundation: a retrospective analysis of a nonprofit foundation. (2011) (1)
- British Committee for Standards in Haematology guidelines for aplastic anemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of 20 × 109/L ‐ RESPONSE to Yan et al (2018) (1)
- SF3B1 Mutant Clones From Patients With Refractory Anaemia With Ringed Sideroblasts (RARS) Originate From The Early Haematopoietic Stem Cells and Maintain Their Engraftment Potential (2013) (1)
- Corrigendum to “Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation” [Journal of Infection 54 (2007) e83–e86] (2007) (1)
- 171 Idarubicin, fludarabine, cytarabine and G-CSF (FLAG-IDA) for the treatment of high risk MDS or AML (1997) (1)
- Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk (2010) (1)
- A randomized trial of hydroxyuea (HY) versus VP16 in advanced adult chronic myelomonocytic leukemia (1994) (1)
- iNucs: inter-nucleosome interactions (2021) (1)
- Microsatellite Instability Induced Mutation in DNA Repair Genes, CTiP and Mre11 Confer Hypersensitivity to PARP Inhibitors in Myeloid Malignancies (2011) (1)
- Allogeneic SCT with matched related and unrelated donors for patients (pts) with refractory anemia (RA): Improved survival after introduction of reduced intensity conditioning (RIC) regimens. (2006) (1)
- Myelodysplastic syndrome . Myelodysplastic Syndrome (2018) (1)
- P147 Management of haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
- Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL (2008) (1)
- P-058 Implementation of an extended Ogata Flow Cytometry Myelodysplasia Score at King's College Hospital (2013) (1)
- Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma. (2006) (1)
- Single HLA Allele Mismatches Are Well Tolerated in the Recipients of T Cell Depleted Reduced Intensity Conditioned Transplants from Unrelated Donors. (2005) (1)
- Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT (2019) (1)
- Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT). (2005) (1)
- Mobilized peripheral blood stem cells compared with bone marrow for related reduced-intensity transplantation in acute myeloid leukaemia in complete remission: a retrospective analysis from the ALWP of EBMT in BONE MARROW TRANSPLANTATION, vol 45, issue , pp S21-S22 (2010) (1)
- Feasibility and Optimal Schedule Of Using Eculizumab In Patients With Hemolytic Paroxysmal Nocturnal Hemoglobinuria (hPNH) With Severe Aplastic Anemia (SAA) Prior To Haemopoietic Stem Cell Transplant (HSCT) (2013) (1)
- Adenovirus infections following allogeneic HSCT. A single UK centre experience (2007) (1)
- IMPACT OF T-CELL DEPLETION STRATEGIES ON OUTCOMES FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR IDIOPATHIC APLASTIC ANEMIA: A STUDY ON BEHALF OF THE EUROPEAN BLOOD AND MARROW TRANSPLANT (EBMT) SAA WORKING PARTY (2018) (1)
- Low Level Residual Extravascular Haemolysis Is Commom Following Eculizumab Treatment In Paroxysmal Nocturnal Haemoglobinuria(PNH), but Does Not Affect Transfusion Requirement (2010) (1)
- C012 Prevalence and prognostic significance of allelic imbalance by single nucleotide polymorphism analysis in low risk myelodysplastic syndromes (2007) (1)
- P035 Improvement in cytogenetic diagnosis and clinical prognostication using SNP-A karyotyping in combination with metaphase cytogenetics in MDS, MDS/MPD and secondary AML (2009) (1)
- RAS gene mutations in Chinese leukaemia patients and members of a family with high incidence of leukaemia. (1996) (1)
- Practical recommendations on the management of non-haematological adverse events in MDS patients treated with lenalidomide (2007) (1)
- TREATMENT WITH VNP40101M (CLORETAZINE?) IN PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES (MDS): RESULTS OF A SUBSET POPULATION IN A PHASE II STUDY (2008) (1)
- Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations (2009) (1)
- Bone marrow failure – causes and complications (2013) (1)
- Incidence and management of veno-occlusive disease following reduced-intensity conditioning haematopoietic stem cell transplantation (2006) (1)
- The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O009) (2020) (1)
- C025 Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin (2007) (1)
- Clinical significance of bone marrow micro metastases in patients undergoing liver transplantation for hepatocellular carcinoma (2006) (1)
- Toxic erythema in the haemato-oncology patient: clinical patterns, triggers and natural history in a series of 16 cases (2006) (1)
- Budd Chiari Syndrome in children: A single centre experience in the United Kingdom (2007) (1)
- Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions (2013) (1)
- Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT). (2004) (1)
- Reduced intensity allogeneic transplantation using BEAM-Campath in patients with lymphoproliferative disease-GVHD, toxicity and survival in 65 patients. (2002) (1)
- Prognostic Significance of Cryptic Genomic Aberrations In AML with Normal Karyotype (2010) (0)
- Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI). (2007) (0)
- SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition (2018) (0)
- Human Erythroid Progenitors are Directly Infected by SARS-CoV-2: Implications for Hypoxia and Emerging Hematopoiesis/Erythropoiesis in COVID19 (2020) (0)
- Spectrum of clinical presentation, histology, treatment and prognosis in a series of eight patients with leukaemia cutis (2004) (0)
- P127 Rates of infection and bleeding are not increased in patients (Pts) with MDS treated with azacitidine (AZA) compared with best supportive care (BSC) (2009) (0)
- CD4+CD25high Foxp3+ Regulatory T-Cells Are Correlated with Different Risk Factors in Myelodysplastic Syndrome (MDS). (2007) (0)
- Telomerase Gene Complex Mutations Are Common in Myelodysplastic Syndromes Patients (2014) (0)
- Apoptin Induced Tumour Specific Killing Via Protein Kinase C Isoforms: A Potential Therapeutic Strategy In Plasma Cell Dyscrasias (2010) (0)
- Mutation and Expression Analysis of Jumonji Genes in Myelodysplastic Syndrome & Acute Myeloid Leukaemia (2014) (0)
- Impact of alemtuzumab versus anti-thymocyte globulin after unrelated allogeneic stem cell transplantation with reduced-intensity conditioning as treatment for AML in CR1: a survey from the Acute Leukaemia Working Party of the EBMT (2012) (0)
- Comparison of four prognostic scores for survival and transformation in MDS (1994) (0)
- Serum Protein Profiling Distinguishes BCR-ABL+ CML from Normal and Neutrophilia Cases. (2005) (0)
- CDKN1A promoter methylation occurs in lymphocytes of MDS patients (2005) (0)
- RPL27A Is a Target for Mir-595 and Contributes to Myelodysplastic Phenotype through Ribosomal Dysgenesis (2014) (0)
- Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-1-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs). (2016) (0)
- Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience (2015) (0)
- Telomere Length and Telomerase Assay Assist in Identifying Novel Telomere Gene Complex Mutations in a Cohort of Patients with Aplastic Anemia (2015) (0)
- Generalized eczematoid graft-versus-host disease: presentation, natural history, and treatment (2005) (0)
- Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2. (1996) (0)
- Improved outcome following reduced intensity conditioned allogeneic haematopoietic stem cell transplantation compared with myeloablative conditioning for acute myeloid leukaemia (2006) (0)
- P-56 CDKN2B (Pl5INK4B) and CDKN1A(P21CIP1) promoter hypermethylation occurs in lymphocytes and not in CD34+ or CD33+ myeloid cells of MDS patients (2005) (0)
- Comparative Analysis of An Azacytidine Versus Azacytidine-HSCT Approach for the Treatment of Older Patients with AML/MDS (2010) (0)
- The acquired CD40L deficiency in B-CLL is reversible and due to contact dependant and independent factors (2004) (0)
- A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab. (2009) (0)
- Use of cDNA microarray analysis to identify cancer testes antigen expression in presentation acute myeloid leukaemia (2004) (0)
- Systems Biology Analysis of Human Primary T Cells Identifies SAP145 as Rate Limiting for the G 1 →S Phase Transition. (2007) (0)
- Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7 (2014) (0)
- Evidence for a macromolecular complex in poor prognostic chronic lymphocytic leukaemia (CLL) that contains CD38, CD49d, CD44, MMP-9 And ZAP-70 (2010) (0)
- Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data. (2004) (0)
- EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG- Single Site Experience (2017) (0)
- Development of a semi-quantitative method for obtaining chimerism data from tissue and archived material (2005) (0)
- Autologous Stem Cell Transplantation Achieves Long-Term Survival in a Selected CNS Lymphoma Population (2014) (0)
- Clinical and Genomic Characterization of Chromosome 7 Lesions in Myeloid Malignancies (2011) (0)
- Reduced Levels of mTOR and TGF- β Signaling Pathway-Associated Proteins in Patients with High Risk MDSsamia AL-Shouli. , Pilar Perezabellan, Frederic Toulza. Shahram Kordasti, Ghulam Mufti (2016) (0)
- The outcome of lymphoproliferative disorder in liver transplant recipients may correlate with age at diagnosis and the use of chemotherapy: A single centre report (2005) (0)
- Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT (2010) (0)
- Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN (2012) (0)
- Assessment of longer-term efficacy, safety, and haematological improvement in the phase 3, randomised, double-blind, placebo-controlled MEDALIST trial of luspatercept to treat anaemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions (2020) (0)
- Myelodysplastic syndrome Diagnostic algorithm for lower-risk myelodysplastic syndromes (2018) (0)
- High titre vectors for targeted expression of multiple genes (2004) (0)
- O-016 Relationship of different platelet response criteria and patient outcomes in a Romiplostim MDS trial (2013) (0)
- Therapy Related Myelodysplastic Syndrome and Acute Myeloid Leukaemia (tMDS/tAML) in Patients Treated with Purine Analogues (PA) for Lymphoproliferative Disorders (LPD); An Association with Alkylator Combination, Dose and Previous Alkylator Therapy. (2009) (0)
- Quality-of-life assessment after haematopoietic stem cell transplant (2009) (0)
- Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells (1997) (0)
- Epigenetic code of primary human T cells during the first cell cycle (2009) (0)
- Comparison of outcome after haplo-identical, HLA-mismatched unrelated donor and unrelated cord blood transplantation in patients with myelodysplastic syndrome (MDS) and secondary acute myeloblastic leukemia (sAML): an EBMT study (2016) (0)
- Development of therapeutic vaccines for cancer and chronic infections: from AML to HBV (2011) (0)
- Mutations of FLT 3 and JAK 2 promote inter chromosomal homologous recombination and the potential for copy neutral loss of heterozygosity ( CN-LOH ) in acute myeloid leukemia (2016) (0)
- Identification of presentation acute myeloid leukaemia antigens in a testes cDNA library (2004) (0)
- Immune Gene Therapy for Acute Myeloid Leukaemia (2010) (0)
- 1131. Generation of Whole Cell Vaccines for Acute Myeloid Leukaemia by Lentivirus Mediated IL-2/CD80 Transduction (2005) (0)
- Title: Mixed T-Cell Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab- Containing Regimen is Shaped by Persistence of Recipient CD8 T Cells (2016) (0)
- Improved disease free survival following reduced intensity conditioned allogeneic stem cell transplantation incorporating alemtuzumab compared with autologous stem cell transplantation in follicular lymphoma (2005) (0)
- P-098 p53 protein expression predicts outcome and cytogenetic response in patients with low-/INT-1-risk myelodysplastic syndromes treated with lenalidomide (2013) (0)
- Increased NHEJ activity in myeloid leukemias is associated with ongoing or induced DNA damage at sites that recruit key NHEJ proteins. (2002) (0)
- MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study (2020) (0)
- rhGM-CSF in Neutropenia Secondary to Myelodysplastic Syndrome (MDS) (1991) (0)
- Pre-Surgical Methylene-Blue “targeting” of Small Intrapulmonary Nodules In Patients with Haematological Malignancies: Preliminary Experience. (2010) (0)
- BRK1: BRICK1, SCAR/WAVE Actin-Nucleating Complex Subunit F-actin: filamentous actin miRNA: microRNA shRNA: short hairpin RNA TCR: T cell receptor WAVE: Wiskott-Aldrich Syndrome Protein (WASP) Family Verprolin-Homologous Protein (2018) (0)
- Inborn Genomic Variation as Predisposing Factors to Myeloid Malignancies. (2009) (0)
- Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: a single institution experience (2006) (0)
- A highly sensitive method for detection of haemopoietic chimerism in allogeneic haemopoietic stem cell transplant recipients (2007) (0)
- In myelodysplastic syndromes (MDS) dendritic cells are phenotypically and functionally different from those obtained in healthy subjects. (1999) (0)
- a stem cell cookie? (2014) (0)
- Molecular, Epigenetic and Gene Expression Profiling of Triple Negative Essential Thrombocythaemia (2019) (0)
- OTU-005 Targeting expanded gut homing effector T cell lineages in GI-GVHD: a new therapeutic paradigm (2018) (0)
- Differential Alemtuzumab Dosage Effects in T-Cell Deplete Allogeneic Haematopoietic Stem Cell Transplants for Myeloid Malignancies- King's College Hospital London Experience (2019) (0)
- Immunoregulatory properties of B-CLL cells (2005) (0)
- Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes (2007) (0)
- Single Nucleotide Polymorphism Array (SNP-A) karyotype is the best predictor of prognosis in normal cytogenetics Acute Myeloid Leukaemia (AML) (2011) (0)
- Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients (2014) (0)
- (B9) Childhood MDS in Turkey — clinical experience in 25 cases (1991) (0)
- Subject Index Vol. 104, 2000 (2001) (0)
- Reducing MCM loading causes chromosomal aneuploidy (2007) (0)
- Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromes. (2006) (0)
- Impact of non-myeloablative conditioning on the frequency of second donation: what should donors be told? (2007) (0)
- 57 A PHASE 2 MULTICENTER STUDY OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WHO FAIL TO ACHIEVE RESPONSE WITH INJECTABLE AZACITIDINE OR DECITABINE (2015) (0)
- Comprar Advances in malignant hematology | H. Saba | 9781405196260 | Wiley (2011) (0)
- Allogeneic stem cell transplantation for patients with refractory anaemia: delayed SCT (> 12 months) results in worse outcome (2007) (0)
- Functional Characteristics of FAS-L Resistant and IL-2 Deprived Regulatory T Cells (Treg A) in Idiopathic Aplastic Anaemia (2017) (0)
- RAS and BCL-2 co-operate in a mouse model of myelodysplasia (MDS). (2003) (0)
- 66 Allogeneic stem-cell transplantation in chronic myelomonocytic leukemia (CMML): Factors affecting transplantation outcome. A study of the CLWP of the EBMT (2011) (0)
- Myelodysplastic Syndrome with Deletion 5q Abnormality and Its Treatment (2006) (0)
- Reduction of Tregs with Expansion of Th1 Cells and Lack of IFN-γ Secretion by GPI Negative T-Cells In PNH (2010) (0)
- Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients (2006) (0)
- The JAK2 V617F Mutation Identifies Specific Subgroups of Myelodysplastic Syndrome (MDS). (2006) (0)
- Liver transplantation for liver failure in association with AL amyloidosis. (2001) (0)
- Direct sequencing of c-fms in myelodysplastic syndrome and AML. (1991) (0)
- RFUSIN2 - a Clinical Grade Lentiviral Vector Co-Expressing CD80/IL-2 Manufactured Under GMP for a Phase I Clinical Trial Study of Immune Gene Therapy for Poor Prognosis Acute Myeloid Leukaemia (2008) (0)
- 'Excess' MCM proteins maintain genomic stability in human cells (2007) (0)
- Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndromes (2015) (0)
- 134 ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN LOWER RISK MDS PATIENTS : A RETROSPECTIVE STUDY ON BEHALF OF THE CMWP OF THE EBMT (2015) (0)
- MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial (2020) (0)
- Therapy at adult T-cell leukaemia/lymphoma: Experience of two London hospitals (1996) (0)
- The ΔN Isoform of the p73 Gene Is Induced during the G0→G1 Transition in Primary Human T Cells. (2007) (0)
- Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) Using Treosulfan Based Compared to Standard Reduced-Intensity or Myeloablative Conditioning Regimens. a Report of the Chronic Malignancies Working Party of EBMT (2020) (0)
- The acquired CD40 ligand deficiency observed in patients with B-CLL is reversible and due to soluble leukaemia derived factor(s) (2004) (0)
- Activating JAK2 tyrosine kinase mutation predicts recurrent Budd-Chiari syndrome post liver transplant (2006) (0)
- Retrospective analysis of the use of valganciclovir in the prevention of cytomegalovirus following stem cell transplantation (2004) (0)
- Retrospective review of prophylaxis for toxoplasmosis following allogeneic bone marrow transplantation (2005) (0)
- Use of autologous bone marrow harvests in patients undergoing volunteer unrelated donor stem cell transplantation: a single-centre experience (2007) (0)
- PARP inhibitor sensitivity in high risk MDS and acute myeloid leukaemia is associated with microsatellite instability dependent frameshift mutations in DNA repair genes (2013) (0)
- B234 Dasatinib and Dexamethasone Combination Therapy Targets Myeloma and the Tumor Microenvironment (2009) (0)
- 137 Clinical potential of mutant ras (1997) (0)
- The JAK2 46/1 Haplotype Analysis In Essential Thrombocythaemia and Polycythaemia Rubra Vera Reveals That CC Genotype Is Associated with a Higher JAK2V617F and c-MPL W515 Allele Burden (2010) (0)
- Cdc2 (cdk1) is aberrantly expressed in CML. (2003) (0)
- 137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group (2011) (0)
- Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival. (2005) (0)
- Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma (2012) (0)
- Luspatercept significantly reduces red blood cell transfusion burden, regardless of gene mutation frequency, spectrum, and prognostic significance, among patients with lower-risk myelodysplastic syndromes enrolled in the MEDALIST trial (2020) (0)
- syndromes single-nucleotide polymorphism analysis in low-risk myelodysplastic Prevalence and prognostic significance of allelic imbalance by (2013) (0)
- Autologous Ex-Vivo Regulatory T Cells(Tregs) Expansion in Aplastic Anemia for Potential Clinical Use (2015) (0)
- Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS. (2005) (0)
- Cancer esearch apeutics , Targets , and Chemical Biology cial Roles for Protein Kinase C Isoforms in Tumor-Specific R ng by Apoptin ng (2010) (0)
- Results of a Phase I/II-Study on PCR-Based Pre-Emptive Therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem Cell Transplantation. (2007) (0)
- Haemophagocytic lymphohistiocytosis post liver transplantation (2004) (0)
- Heterozygous RTEL1 Variants Are Associated with Bone Marrow Failure and Abnormal Clinical Phenotype (2016) (0)
- Abstract B124: Immunotherapy of acute myeloid leukemia using Vg9Vd2 T-cells (2016) (0)
- Single agent cloretazine is an effective induction therapy in elderly patients (pts) with poor risk AML (2006) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Myelodysplastic Syndromes 50 Years or Older. A Retrospective Survey from the EBMT. (2006) (0)
- Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study (2016) (0)
- A Review of 1000 Molecular Investigations of Rare Inherited Anaemia and Related Conditions with the Red Cell Gene Panel (2018) (0)
- Poor risk assessment in the elderly receiving cloretazine induction for AML or MDS. (2006) (0)
- CD38 expression in B-CLL is not fixed and may change due to contact with activating stimuli found within the leukaemic microenvironment (2005) (0)
- First international symposium on myelodysplastic syndrome (1989) (0)
- Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity (2014) (0)
- Idiopathic CD4+ T-lymphocytopenia. (1992) (0)
- Comparison of Outcome after Allogeneic Stem Cell Transplantation in AML Patients in First or Second Complete Remission Following Either Fludarabin/Busulfan, Flamsa-TBI or Flamsa-Bu Conditioning (2017) (0)
- Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation (2012) (0)
- Increased incidence of autoimmune cytopenia and paraproteinemia following allogeneic bone marrow transplants conditioned with Alemtuzumab. (2003) (0)
- Internal Tandem Duplication Mutation of FLT3 (FLT3/ITD) Significantly Increases Inter Chromosomal Homologous Recombination Providing a Direct Link Between Constitutive FLT3-ITD Activity and Propagation of Copy Neutral Loss of Heterozygosity (CN-LOH) in Acute Myeloid Leukaemia (2014) (0)
- SINGLE UK CENTRE EXPERIENCE OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOMONOCYTIC LEUKEMIA (2008) (0)
- A novel approach to MRD monitoring in AML, realtime quantification of leukaemia associated antigens (WT1, PRAME and G250) (2005) (0)
- The effect of the B-CLL microenvironment on CD38 expression by the malignant clone (2007) (0)
- Microdeletion at the acetylcholinesterase locus at 7q22 associated with myelodysplasia and acute myeloid leukaemia (1994) (0)
- Late Relapses Following Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by Cellular Therapy. (2009) (0)
- IL-2/B7.1 (CD80) fusagene transduction of AML blastsby a self-inactivating lentiviral vector (2005) (0)
- 117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) (2015) (0)
- Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML. (2012) (0)
- 25. The Myelodysplastic Syndromes (2015) (0)
- 18FDG-PET positron emission tomography (PET) is highly predictive of outcome following autograft for relapsed lymphoma. A retrospective study of 41 patients. (2002) (0)
- The Scope of Viral Vectors for the Transduction of Haemopoietic Cells. (1998) (0)
- Role of allogeneic SCT in low risk MDS : A Retrospective Study on Behalf of the CMWP of the EBMT (2015) (0)
- Spontaneous myonecrosis in chronic myeloid leukaemia (2016) (0)
- CHAPTER 7 – The myelodysplastic syndromes (2009) (0)
- Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance (2017) (0)
- The reactivities of bone marrow cells with K167, bromodeoxyuridine and GM-CSF MoAbs in childhood MDS (1991) (0)
- Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations (2019) (0)
- Retrovirus-mediated gene transfer of B7.1 into primary acute myeloid leukaemia blasts (1995) (0)
- 14 Cytogenetics of myelodysplastic syndromes and detection of del 5q (2007) (0)
- The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML. (2006) (0)
- MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS) (2020) (0)
- 149 Treatment strategies in MDS: Who and how should be treated? (1997) (0)
- A report on a rare jumping translocation involving chromosome reqion 1q12 in a patient with myeloid disease (2007) (0)
- A single centre experience of reduced intensity conditioned HSCT using BEAM-campath for low-grade lymphoid malignancies (2004) (0)
- P53 Protein Expression Correlates with Adverse Outcome in Low-Risk Myelodysplastic Syndromes (2016) (0)
- High incidence of therapy-related myelodysplasia and acute myeloid leukaemia (tMDS/tAML) following treatment with fludarabine and cyclophosphamide for low grade lymphoproliferative disorders (2006) (0)
- Reduced-Intensity Transplants - Red Cell Antigens, Antibodies, and Blood Product Usage. (2006) (0)
- Prevalence and Clinical Significance of Heparin Induced Thrombocytopenia in Patients Transplanted for Budd Chiari Syndrome (2010) (0)
- P072 Genomic profiling of CD34+ and CD61+ cells in 5q-syndrome (2007) (0)
- EBV REACTIVATION ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE, CLONAL GAMMOPATHY AND OUTCOMES IN ALLOGENEIC T-CELL DEPLETED STEM CELL TRANSPLANTS FOR MYELOID MALIGNANCIES (2019) (0)
- Defining quiescence and the G(0)-> G(1) commitment point by gene expression analysis. (2003) (0)
- rhGM-CSF in Neutropenia Secondary to HIV Infection (1991) (0)
- Long-term survival of patients with MDS after allogeneic transplantation : a report from the Chronic Malignancies Working Party of EBMT (2017) (0)
- Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors (1992) (0)
- Association of sarcoidosis with haematological malignancies and secondary dysplastic features. A single centre experience (2006) (0)
- Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions (2011) (0)
- Zinc Finger Nuclease (ZFN) Targeted Homologous Recombination Assay Detects Elevated Inter Homologous Recombination Activity and Copy Neutral Loss of Heterozygosity (CN-LOH) in Internal Tandem Duplication Mutated FLT3 (FLT3-ITD) Acute Myeloid Leukaemia (AML) (2015) (0)
- P038 Inhibition of poly ADP ribose polymerase (PARP) induces cell death in leukaemic cell lines alone or synergistically with histone deacetylase inhibitors: potential for anti-leukaemia therapy (2007) (0)
- Bone Marrow Stem Cells from Patients with Myelodysplastic Syndrome (MDS) Engraft and Migrate in-between the Humanized Niches in Immuno-Compromised Mouse Models (2017) (0)
- Donor Lymphocyte Infusions Correct Deficiency of Naive T Cells and Improve T-Cell Competence after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte Depletion (2016) (0)
- Myeloid Derived Suppressor Cell Expansion Correlates With Increased regulatory T Cells In Myelodysplastic Syndrome (2013) (0)
- Book Review / Announcements (1983) (0)
- PRE-TRANSPLANT SERUM FERRITIN AS AN INDEPENDENT PROGNOSTIC FACTOR IN MDS PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING HSCT (2008) (0)
- Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report. (2005) (0)
- Dendritic Cell Subsets in Bone Marrow and Peripheral Blood of Patients with Myelodysplastic Syndromes Display Numeric and Functional Defects (2015) (0)
- Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT (2016) (0)
- myelodysplastic syndrome Utility of peripheral blood for cytogenetic and mutation analysis in (2013) (0)
- Mitoxanthrone-induced acute myeloid leukaemia presenting with leukaemia cutis. (2013) (0)
- Lymphocytes, but not CD34+ or CD33+ myeloid cells, of MDS patients have a hypermethylated CDKN2B promoter (2005) (0)
- Expansion of Polyclonal CD4+CD25high Foxp3+ Regulatory T-Cells in High Risk Myelodysplastic Syndromes (MDS). (2006) (0)
- Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion. (2009) (0)
- P-55 5 Azacytidine in myelodysplasticsyndromes: Correlation between clinical responses and CDKN2B promoter methylation (2005) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the Cmwp of the EBMT (2014) (0)
- Reconstruction of Human AML Reveals Stem Cell Origin and Therapeutic Targets for Treatment Resistant CD34-/Lo MLL-Rearranged Leukemia (2019) (0)
- Cancer survivorship: A pilot study exploring responses of Bone Marrow Transplant survivors to a life-coaching intervention (2013) (0)
- Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. (2020) (0)
- P94 Prevalence and clinical significance of heparin induced thrombocytopaenia in patients transplanted for Budd Chiari syndrome (2010) (0)
- Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones (2009) (0)
- TAT-Apoptin Mediated Induction of Apoptosis in Leukaemic Cells. (2006) (0)
- Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML). (2010) (0)
- 332 Outcomes of reduced intensity conditioning HSCT for lower-risk MDS: King's college hospital experience (2011) (0)
- Patterns of engraftment of T-cells, granulocytes, B-cells, NK cells and dendritic cells (BDCA1 and BDCA4) following RIC allo HSCT (2005) (0)
- High Resolution Genomic Mapping of Breast Cancer Derived T-MDS/TAML (2008) (0)
- Idiopathic CD4+ T-lymphocytopenia. Authors' replies (1992) (0)
- A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST t (2016) (0)
- 46 Recent developments in the prognostic classification for MDS: Results of The International Risk Analysis Workshop (1997) (0)
- Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial. (2003) (0)
- Myeloid Leukemia Antiapoptotic Microenvironment of Acute (2004) (0)
- Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004 (2013) (0)
- BRIEF REPORT (2013) (0)
- T-Cell Profiling Shows Marked Differences in Gene Expression Between Tumour Infiltrating (TIL) and Peripheral Blood (PB) Antibody-Bead Selected T-Cells From Fresh Lymph Node and PB Samples in Follicular Non-Hodgkin's Lymphoma (FL): Possible implications for Immunomodulatory Therapy (2012) (0)
- Investigation of disease kinetics in CML patients with b3a2 and b2a2 BCR-ABL fusion transcripts undergoing Imatinib treatment (2007) (0)
- An Unusual Expression: The Tumour Antigen SSX2IP Is Preferentially Expressed on the Surface of Acute Myeloid Leukaemia Cells during Early Mitosis. (2006) (0)
- Cytogenetic characterisation in a patient with concomitant multiple myeloma and CLL (2008) (0)
- Relapse risk score after allogeneic stem cell transplantation for MDS patients. An EBMT study from the MDS subcommittee of Chronic Malignancies Working Party (CMWP) (2016) (0)
- Development of a novel DNA vaccine encorporating a PASD1 analogue peptide which can enhance anti-leukaemia T cell responses in vitro and in vivo (2010) (0)
- Single Cell Mass Cytometry Identifies T-Regulatory Cell Subsets Associated with ECP Response in Chronic GVHD (2016) (0)
- Response to Peggs et al. (2003) (0)
- Plerixafor Ex Vivo Mobilization of Placental Derived Haematopoietic Stem Cells (2011) (0)
- 1244 Immunocytochemical detection of hepatocellular carcinoma micrometastases using HEP PAR-1 monoclonal antibody in patients undergoing liver transplantation (2003) (0)
- nucleotide polymorphism analysis in low risk myelodysplastic syndromes Prevalence and prognostic significance of allelic imbalance by single (2013) (0)
- Single centre experience of allogeneic haematopoietic stem cell transplantation for chronic myelomonocytic leukaemia (2008) (0)
- Increased Effector CD4+ T-Cells Early Post Hematopoietic Stem Cell Transplantation Using an Alemtuzumab-Based Reduced Intensity Conditioning Regimen Correlate with Subsequent Development of Graft Versus Host Disease. (2007) (0)
- mutations in acute myeloid leukemia promote interchromosomal homologous recombination and the potential for copy neutral loss of heterozygosity (CN-LOH) (2017) (0)
- Invasive pulmonary aspergillosis is not a contraindication to reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation (RIC allo-HSCT) (2004) (0)
- Analysis of T599A B-RAF. (2013) (0)
- Dysfunctional Tregs with Absence of Cytokine-Secreting CD4 + T-Cell Subsets and Marked Expansion of Th1 Cells Is a Hallmark of Idiopathic Aplastic Anaemia (AA) (2010) (0)
- Bone marrow failure: causes and complications (0)
- Cytokine Profile of Patients with Invasive Apsergillosis- Preliminary Results. (2010) (0)
- Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL)[Abstract] (2007) (0)
- Telomere Gene Complex Mutations Are Frequently Found with Shortened Telomeres in Bone Marrow Failure Syndromes and Idiopathic Pulmonary Fibrosis; Correlation with Haematological and Clinical Features (2014) (0)
- Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen is Shaped by Persistence of Recipient CD8 T Cells. BIOLOGY OF BLOOD AND MARROW (2017) (0)
- Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis (2016) (0)
- Survivorship following bone marrow transplant: a pilot study exploring responses to a life-coaching intervention (2011) (0)
- Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies (2015) (0)
- Myelodysplastic syndrome. (2003) (0)
- Chronic Relapsing Remitting Sweet’s Syndrome- a Harbinger Of Myelodysplastic Syndrome (MDS), Single Centre Analysis Of 31 Patients (2013) (0)
- Generalized eczematoid graft-vs.-host disease: presentation and natural history (2005) (0)
- adults : recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in (2013) (0)
- Retrospective review of patients with high risk of HBV disease undergoing reduced intensity conditioned (RIC) allogeneic BMT (2005) (0)
- The pathophysiology and management of HIV-associated haematological abnormalities. (1993) (0)
- C3) Chromosomal deletions in haematological malignancies (1991) (0)
- Expansion of CD141 int Dendritic Cells in Myelodysplastic Syndrome (MDS) (2012) (0)
- Toxic shock syndrome complicated by laryngeal oedema. (1983) (0)
- Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). (2020) (0)
- Characteristics and Outcome Of Acute Myeloid Leukemia Following Breast Cancer: Analysis Of 408 Cases and Controls (2013) (0)
- Human cancer DNA fingerprint analysis. (1987) (0)
- Alemtuzumab vs ATG for T-Cell Depletion in Sibling Donor Reduced Intensity Haematopoietic Stem Cell Transplantation (RIC HSCT) for the Treatment of Acute Myeloid Leukaemia and Myelodysplastic Syndrome (2011) (0)
- Reduced intensity transplantation for myelofibrosis: a single centre experience (2008) (0)
- Acquired Somatic Uniparental Disomy is a Chromosomal Defect Important in Predicting Treatment Responses and Survival Outcomes in MDS, MDS/MPN and Secondary AML (2009) (0)
- Application of a new strategy to identify regulators of a signalling pathway in human immune cells (2011) (0)
- Cross-lineage rearrangement of antigen receptor genes in atypical chronic myeloid leukemia. (1991) (0)
- Acquired aplastic anaemia and pure red cell aplasia (2020) (0)
- Systemic AL amyloidosis related liver failure; the role of liver transplantation. (2001) (0)
- Optimising the use of arsenic trioxide in 'high risk' acute promyelocytic leukaemia (APL): The UK experience. (2005) (0)
- The inhibitory effects of multiple tumor derived soluble factors on apoptosis and T cell function in the leukemic microenvironment. (2002) (0)
- Minimal criteria for diagnosis of MDS (2006) (0)
- Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation (2014) (0)
- A Phase I trial of talazoparib in patients with advanced hematologic malignancies (2021) (0)
- High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy (2008) (0)
- An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML (2015) (0)
- Results of a BSBMT phase I/II-study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following reduced intensity allogeneic stem cell transplantation (2008) (0)
- P-248 Dendritic cell subsets in myelodysplastic syndromes (2013) (0)
- B-CLL cells secrete factors including IL-6 which inhibit T cell proliferation and activation and promote Th2 polarisation (2007) (0)
- Fanconi-Like Syndrome with Negative Chromosomal Breakages Test and High Incidence of Myelodysplasia. (2007) (0)
- Towards the Potential Use of In Vitro Expanded Regulatory T-Cells (Tregs) in Aplastic Anemia (AA): Opportunities for Therapy (2016) (0)
- Mono- and biclonal gammopathies following conditioning regimens incorporating alemtuzumab for haemopoietic stem cell transplantation (2003) (0)
- Contents Vol. 104, 2000 (2001) (0)
- Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features (2019) (0)
- Hepatocyte Growth Factor Expression in Bone Marrow Microenvironment Is Critical for Progression of MGUS to Myeloma. (2007) (0)
- 111 MUTATIONAL PROFILE AND KARYOTYPIC ABNORMALITIES OF CLINICAL TRIAL PATIENTS WITH HIGHER-RISK MDS FOLLOWING FAILURE OF HYPOMETHYLATING AGENTS (HMAS): IMPACT ON RESPONSE TO RIGOSERTIB THERAPY (2015) (0)
- Epigenetic analyses of T cells during the G0 to G1 transition (2008) (0)
- Liver function abnormalities following alemtuzumab (Campath-1H): A previously unrecognised first dose effect (2005) (0)
- tumor microenvironment CD38 expression in chronic lymphocytic leukemia is regulated by the (2013) (0)
- Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs) (2015) (0)
- Increased non homologous and joining (NHEJ) efficiency and infidelity in myeloid leukaemia: A possible mechanism for chromosomal deletions in cancer. (2000) (0)
- 63 Long-term outcomes following RIC HSCT for MDS with fludarabine, busulphan and alemtuzumab (2011) (0)
- The clinical and histopathological spectrum of neutrophilic inflammatory disease encountered in the setting of myelodysplastic syndrome (2021) (0)
- Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes (2021) (0)
- Increased Number of IL-17 Producing CD4(+) T Cells in Low Risk Myelodysplastic Syndrome (MDS) (2008) (0)
- Changing landscapes in haematopoietic stem cell transplantation for haematological malignancy (2009) (0)
- The Myelodysplastic Overlap Syndromes (2011) (0)
- Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation. (2007) (0)
- Engraftment of donor langerhans cells following allogeneic stem cell transplantation with reduced intensity conditioning (RIC) is delayed compared to other myeloid lineages (2007) (0)
- Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT (2014) (0)
- Dual Src/Abl Kinase Targeted Inhibition in Myeloma Microenvironment Promotes Myeloma Cell Apoptosis Both in Vitro and In Vivo (2009) (0)
- MDS myelodysplastic syndromes and acute myeloid leukemia secondary to related proteins in the - The role of apoptosis, proliferation, and the Bcl-2 (2013) (0)
- 225 Retrospective review of treatment of patients with concurrent t-large granular lymphocytosis and myelodysplastic syndrome (2011) (0)
- Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes. (2010) (0)
- Evidence for A Macromolecular Complex in Poor Prognostic CLL That Contains CD38, CD49d, CD44, MMP-9 and ZAP-70 (2009) (0)
- Immune reconstitution of severe combined immune deficient (SCID) mice: A potential model for testing immune gene therapy for acute myeloid leukaemia (1995) (0)
- Primary AML cell supernatant inhibits T cell and neutrophil apoptosis. (2001) (0)
- Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies (2014) (0)
- Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes (2011) (0)
- Dysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes (2023) (0)
- CD38 expression in B-CLL is dynamic and influenced by cell contact in the leukaemic microenvironment (2007) (0)
- VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients. (1995) (0)
- Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party (2013) (0)
- C031 Allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndromes 50 years or older. A retrospective survey from the European Group for Blood and MarrowTransplantation (2007) (0)
- In-Situ Proliferation May Explain the Persistence of Host Derived Langerhans Cells Following Allogeneic Hematopoietic Stem Cell Transplantation with Reduced Intensity Conditioning. (2007) (0)
- patients for lymphoproliferative diseases: GVHD, toxicity and survival in 65 BEAM-Campath reduced intensity allogeneic stem cell transplantation (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ghulam J. Mufti?
Ghulam J. Mufti is affiliated with the following schools:
